2
Clinical Trials associated with CD19&CD20 bispecific CAR-T cells(Wuhan Union Hospital)The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 & CD22 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
The Safety and Efficacy of CD19 & CD20 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 & CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
100 Clinical Results associated with CD19&CD20 bispecific CAR-T cells(Wuhan Union Hospital)
100 Translational Medicine associated with CD19&CD20 bispecific CAR-T cells(Wuhan Union Hospital)
100 Patents (Medical) associated with CD19&CD20 bispecific CAR-T cells(Wuhan Union Hospital)
100 Deals associated with CD19&CD20 bispecific CAR-T cells(Wuhan Union Hospital)